Exchange: NASDAQ·Updated 07:30 PM EST

XENE News

News
all
press releases
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?
Xenon pauses enrollment in late-stage depression trials after unexpected side effects, while its epilepsy pipeline offers growth potential.
Zacks
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?
Xenon pauses enrollment in late-stage depression trials after unexpected side effects, while its epilepsy pipeline offers growth potential.
Zacks
More News
CEO Ian Mortimer and CFO Thomas Kelly purchased 45,000 shares of XENE in the open market.
Stocktwits
Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Xenon Pharmaceuticals Inc. (Xenon or the Company) (NASDAQ: XENE) for violations of the securities laws. INVESTIGATION DETAILS: The investigation...
Business Wire
Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE) Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)PR NewswireNEW YORK, Sept. 22, 2026...
PR Newswire
Xenon Pharmaceuticals Stock Sinks 31% After Pausing Depression Study Enrollment...
Yahoo! Finance: News
Here are some of the companies making headlines in midday trading...
CNBC: Top News
Xenon Pharmaceuticals submits an FDA application for azetukalner for seizures while voluntarily pausing enrollment in depression trials.read more...
Benzinga
Xenon files an FDA application for azetukalner in epilepsy as its depression studies face a temporary enrollment pause.
Zacks
Xenon Pharmaceuticals shares fell 25% after hours after pausing new patient enrollment in ongoing psychiatry clinical studies.read more...
Benzinga
Major U.S. indices closed higher on Thursday, with the Dow Jones Industrial Average rising 0.61% to 51,778.04read more...
Benzinga

Advertisement|Remove ads.